

Special Issue

Advanced Molecular Research on Pathology, Prevention, Diagnosis and Treatments for Knee Osteoarthritis

Message from the Guest Editor

Knee osteoarthritis (OA) is a common disease caused by degeneration or trauma in joints that contributes to inflammation in the synovium, articular cartilage, and subchondral bone. Pathological changes are observed in knee OA, including synovitis, loss of extracellular matrix in the articular cartilage, chondrocyte death, tissue fibrosis, and cyst and osteophyte formation. Knee pain is a major symptom of OA that bothers people of all ages on a daily basis. There are also many other significant symptoms of knee OA, including swelling, stiffness, creaking joints, and difficulty in moving, which affect patients every day. The molecular mechanism of knee OA still needs to be explored further through clinical and preclinical studies. Determining how to identify, discover, and treat problems linked to knee OA are topics of concern and challenges for scientists around the world. Therefore, advances in molecular research in the pathology, prevention, diagnosis, and treatment of knee OA are within the scope of this Special Issue. Summaries of new findings, concepts, and molecular study directions in the form of review articles are also of interest in the Special Issue.

Guest Editor

Dr. Jai-Hong Cheng

Center for Shockwave Medicine and Tissue Engineering, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Kaohsiung 833, Taiwan

Deadline for manuscript submissions

closed (31 July 2022)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/103715

Biomedicines
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.3 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).